Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Risk/Benefit Of CAR-T For Autoimmune Diseases May Shift With FDA Investigation

Use Could Be Restricted To Most Severe Patients

Executive Summary

CAR-T therapy-associated T-cell malignancies that the US FDA is investigating could make the treatments less attractive in autoimmune diseases than in oncology, but patients in both settings already accept some cancer risk with other available medicines.

You may also be interested in...



Precision Sells Off Autoimmune Rights For Allogeneic CAR-T To TG Therapeutics

TG, which has seen growing sales for Briumvi in multiple sclerosis, is expanding into CAR-T for immunology as Precision pivots to in vivo gene therapies.

Allogene’s Cema-Cel Goes Express As Company Shifts To First-Line LBCL

The allogeneic CAR-T developer announced a significant shift in its business strategy to develop its lead candidate in first-line consolidation of LBCL as the third-line disease setting becomes saturated.

J&J/Legend Tout Carvykti In Earlier Lines As Competitors Move In

They have new data for the CAR-T after one to three lines of multiple myeloma treatment and Phase III patient-reported outcomes data, but Gilead and Gracell are nipping at the companies’ and BMS’s heels.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149429

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel